Watson Revises Generics Focus to Achieve $600 Million Watson Pharmaceuticals has realigned its sales force following its acquisition of Arrow Group to increase its focus on urology, obstetrics and gynecology treatment areas and certain primary care markets.
Cephalon Physician Payments Go Public Following CIA Cephalon is disclosing payments to physicians and related entities as required by a corporate integrity agreement (CIA) it entered in a settlement with the HHS Office of Inspector General.
Overhaul’s Failure Will Ignite US Health Industry Mergers Insurers, drugmakers and hospitals will likely slash costs and merge companies to maneuver through a U.S. health-care landscape marked by rising medical expenses and the loss of millions of potential paying customers.
Few Women Take Tamoxifen to Prevent Breast Cancer Researchers with the National Cancer Institute have found that the prevalence of tamoxifen use for the prevention of breast cancer among women without a personal history of breast cancer is very low.
FDA Raises Concerns About Cell Therapeutics’ Cancer Drug Drug reviewers working for the Food and Drug Administration raised concerns about the efficacy and safety of Cell Therapeutics’ lymphoma drug pixantrone drug, according to a review of the drug posted to the agency’s Web site Monday.
Almirall Gets EU Approval for Prostate Drug Spanish drug firm Almirall said on Monday it had received European Commission approval to sell silodosin to treat BPH, the enlargement of the prostate gland which affects middle-aged and elderly men.
Lupin Gets FDA Nod to Sell Blood Pressure Drug Drug maker Lupin Ltd Monday said it has received final approval from the US drug regulator for marketing Amlodipine-Benazepril capsules, used for treating high blood pressure, in America.
